Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Immune Globulin Intravenous, Human
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Grifols’ Biotest: FDA Approves Yimmugo for Primary Immunodeficiencies
Details : Yimmugo is an innovative intravenous immunoglobulin (Ig) therapeutic, which is now approved for the treatment of patients with primary immunodeficiencies.
Product Name : Yimmugo
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
June 17, 2024
Lead Product(s) : Immune Globulin Intravenous, Human
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trimodulin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Biotest AG: Biotest Treats First Covid-19 Patient with Trimodulin
Details : First patient with severe COVID-19 was treated in Spain with trimodulin in the ESsCOVID (Escape from severe COVID-19) trial. Biotest aims for an expedited approval of trimodulin to rapidly respond to the need for novel treatment options for patients with...
Product Name : BT588
Product Type : Antibody
Upfront Cash : Inapplicable
June 10, 2020
Lead Product(s) : Trimodulin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
